SCHEMBL760904

SCHEMBL760904

O=C1c2ccccc2C(=O)c2c(F)cccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.57
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
CDC25B P30305 1/20 0.55
TTR P02766 1/20 0.53
ALDH1A1 P00352 6/20 0.52
MAPT P10636 6/20 0.52
MAPK1 P28482 6/20 0.52
L3MBTL1 Q9Y468 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
EGFR P00533 3/20 0.52
RAB9A P51151 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
LMNA P02545 2/20 0.52
PABPC1 P11940 1/20 0.52
NSD2 O96028 1/20 0.52
MAOA P21397 7/20 0.48
ALOX12 P18054 2/20 0.48
BCL2 P10415 2/20 0.48
MCL1 Q07820 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10716838 0.93 MAOA (0.52) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL8669578 0.91 MEN1 (0.55) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL2072999 0.91 MAPT (0.52) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL8916299 0.91 MAPT (0.54) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL13487410 0.86 PTPRC (0.57) ADORA2AMEN1KMT2ACDC25BALDH1A1
SCHEMBL13487411 0.86 PTPRC (0.59) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL5866470 0.83 CA1 (0.52) MEN1KMT2ACDC25BTTRALDH1A1
SCHEMBL13487412 0.83 CA1 (0.52) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL3418850 0.83 MEN1 (0.55) ADORA2AMEN1KMT2ACDC25BTTR
SCHEMBL8659735 0.82 ADORA2A (0.41) ADORA2AMEN1KMT2ACDC25BTTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110283064-A A kind of 9,10- anthraquinone derivative and its preparation method and application 武汉依麦德新材料科技有限责任公司 2019-09-27 CN claimed
CN-106916305-A A kind of super cladodification polyimides containing anthraquinone ring and preparation method thereof 宁波祢若电子科技有限公司 2017-07-04 CN claimed
US-5385842-A Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-31 US claimed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP claimed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP claimed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO claimed
CN-117597327-A Pharmaceutical preparation 第一波动生物制药股份有限公司 2024-02-23 CN disclosed
US-20200270200-A1 DEUTERATED COMPOUNDS AND USES THEREOF OncoTherics Ventures Limited (GB) 2020-08-27 US disclosed
CN-110283064-A A kind of 9,10- anthraquinone derivative and its preparation method and application 武汉依麦德新材料科技有限责任公司 2019-09-27 CN disclosed
US-10385009-B2 Deuterated compounds and uses thereof BIOSTATUS LIMITED (GB) 2019-08-20 US disclosed
EP-2882708-B1 NEW COMPOUNDS AND USES THEREOF BIOSTATUS LTD (GB) 2018-10-03 EP disclosed
EP-1948738-B1 COLOURED PARTICLES FOR ELECTROPHORETIC DISPLAYS BASF SE (DE) 2018-02-28 EP disclosed
CN-106458821-A BH4 antagonists and methods related thereto 爱默蕾大学 2017-02-22 CN disclosed
WO-2007048722-A2 PROCESS FOR HAIR DYEING COMPRISING APPLICATION OF COMPOSITE PIGMENT CIBA HOLDING INC. (CH) 2007-05-03 WO disclosed
WO-2007048721-A1 COLOURED PARTICLES FOR ELECTROPHORETIC DISPLAYS CIBA HOLDING INC. (CH) 2007-05-03 WO disclosed
US-6919453-B1 Colorant compositions THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2005-07-19 US disclosed
US-5385842-A Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-31 US disclosed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP disclosed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP disclosed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385009-B2 Deuterated compounds and uses thereof HIF1AN, HIF1A, EGLN2 ADORA2A 1782/4885MEN1 2943/4885KMT2A 2099/4885
US-20200270200-A1 DEUTERATED COMPOUNDS AND USES THEREOF HIF1AN, HIF1A, EGLN2 ADORA2A 1800/4885MEN1 2862/4885KMT2A 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.